Geographical distribution of TTR met30 carriers in northern Sweden: discrepancy between carrier frequency and prevalence rate.
about
Therapeutic Oligonucleotides Targeting Liver Disease: TTR AmyloidosisSixty years of transthyretin familial amyloid polyneuropathy (TTR-FAP) in Europe: where are we now? A European network approach to defining the epidemiology and management patterns for TTR-FAPA possible role for miRNA silencing in disease phenotype variation in Swedish transthyretin V30M carriers.Detection of a variant protein in hair: new diagnostic method in Portuguese type familial amyloid polyneuropathy.Support for the multigenic hypothesis of amyloidosis: the binding stoichiometry of retinol-binding protein, vitamin A, and thyroid hormone influences transthyretin amyloidogenicity in vitro.The relative amounts of plasma transthyretin forms in familial transthyretin amyloidosis: a quantitative analysis by Fourier transform ion-cyclotron resonance mass spectrometry.Transthyretin mutations in hyperthyroxinemia and amyloid diseases.Guideline of transthyretin-related hereditary amyloidosis for clinicians.TTR familial amyloid polyneuropathy: does a mitochondrial polymorphism entirely explain the parent-of-origin difference in penetrance?Recent progress in the understanding and treatment of transthyretin amyloidosis.Sequence-dependent denaturation energetics: A major determinant in amyloid disease diversity.Fibrinogen A alpha chain Leu 554: an African-American kindred with late onset renal amyloidosis.A novel transthyretin variant p.H110D (H90D) as a cause of familial amyloid polyneuropathy in a large Irish kindred.Amyloid Cardiomyopathy in Hereditary Transthyretin V30M Amyloidosis - Impact of Sex and Amyloid Fibril Composition.Involvement of Macrophages in the Pathogenesis of Familial Amyloid Polyneuropathy and Efficacy of Human iPS Cell-Derived Macrophages in Its TreatmentPeripheral Blood Cell Gene Expression Diagnostic for Identifying Symptomatic Transthyretin Amyloidosis Patients: Male and Female Specific Signatures.Heterogeneity of penetrance in familial amyloid polyneuropathy, ATTR Val30Met, in the Swedish population.Transthyretin-related familial amyloidotic polyneuropathy-Progress in Kumamoto, Japan (1967-2010)-.Model for end-stage liver disease exceptions in the context of the French model for end-stage liver disease score-based liver allocation system.Diagnosis of familial amyloid polyneuropathy: wide-ranged clinicopathological features.Waiting for a liver transplant: the experience of patients with familial amyloidotic polyneuropathy.Early liver transplantation is essential for familial amyloidotic polyneuropathy patients' quality of life.The neuroendocrine system and gastrointestinal complications in patients with familial amyloidosis and polyneuropathy.Description of transthyretin S50A, S52P and G47A mutations in familial amyloidosis polyneuropathy.Reduction of free radical activity in amyloid deposits following liver transplantation for familial amyloidotic polyneuropathy.Changes in pathological and biochemical findings of systemic tissue sites in familial amyloid polyneuropathy more than 10 years after liver transplantation.Successful pregnancies and fatherhood in familial amyloidotic polyneuropathy (FAP Val30Met) patients with liver transplantation.Amyloid polyneuropathy caused by wild-type transthyretin.Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm.Life paths of patients with transthyretin-related familial amyloid polyneuropathy Val30Met: a descriptive study.Late-onset familial amyloid polyneuropathy type I (transthyretin Met30-associated familial amyloid polyneuropathy) unrelated to endemic focus in Japan. Clinicopathological and genetic features.Hsf-1 affects podocyte markers NPHS1, NPHS2 and WT1 in a transgenic mouse model of TTRVal30Met-related amyloidosis.Epidemiological, clinical and genetic study of familial amyloidotic polyneuropathy in Cyprus.Frequency of the transthyretin Val30Met mutation in the northern Swedish populationSelection of hereditary transthyretin amyloid patients for liver transplantation: the Swedish experienceReport of five rare or previously unknown amyloidogenic transthyretin mutations disclosed in SwedenInvestigation into thiol conjugation of transthyretin in hereditary transthyretin amyloidosisDifficulties in clinical diagnosis and prediction of outcome in patients with the transthyretin Met 30 mutation: Report of two casesJapanese monozygotic twins with familial amyloidotic polyneuropathy (FAP) (ATTR VaBOMet)Gastrointestinal dysfunction in familial amyloidotic polyneuropathy (ATTR Val3 et) - comparison of Swedish and Japanese patients
P2860
Q26782089-612166DE-8423-4799-AAA2-090CBA714687Q28078350-1DBF260C-6AE6-49A6-A47B-9C694CA00BEDQ33692348-93227EF0-DDAD-4A85-9FFD-67328E825C65Q33791776-4A5F7741-ADEE-4758-9AC3-80D773A66DACQ33949040-2BFE12AA-012D-4945-BAAE-12FDA8A3819FQ34073701-278DA6A3-8009-4EE4-823E-9A0F3158A5E1Q34269382-0010DD7E-7631-4302-BE15-02EE2A0BF5D4Q34328734-0E653F43-B39E-4A2D-B10C-8201D6A3F5A4Q34329412-10081E5F-0D8D-4D99-8F9A-B5298AFE6B13Q34416193-5A79126D-20D9-4F8A-A599-3117D2ACCB8DQ34443897-1A78944B-0E30-4461-BFC3-5F078944F26CQ34480186-4CF721C2-3424-4535-A58D-23AF17068D98Q35456927-A5B107DA-C187-4882-95F6-8E3CB1400B6AQ35850786-A3930130-20D9-4A69-9BDB-66616B6A1B11Q36151383-7921166E-D1D5-4AD4-8243-49CB4AE0216CQ37202287-4BAF5F07-BB59-4E0F-80BB-74497AE4B06DQ37335475-03376758-67BA-4768-8642-B818C56B45E3Q37778217-9FFDA5BC-EECF-462F-A481-7EC587821FEAQ37893109-C41F7EC3-FD2D-4F8A-8235-18FC1A130233Q38089871-A70A137C-953D-464F-B7EC-DC4C3175681FQ39425999-85ECD040-59A9-4C8F-A0AF-89C2BA953F52Q40714600-82291A98-DCF6-411D-990B-986A65043611Q41595462-9FEA762D-7EB5-4C27-BA47-4D036EA66BA1Q43471530-63D9E478-981A-4154-878D-FE8ECF78B9E3Q43924602-9AC67151-17A0-443A-AB82-78082FAB906DQ44155172-50E9E79F-6F80-4E16-98E9-306F6FBF9366Q45102168-CA16B379-9498-4E66-A7E8-B94839EFBA87Q46104326-B59DEE09-22C4-48C0-8E90-725B26633B4BQ47561760-21ACD112-AD41-460C-9222-A84D957B7F6BQ47593376-0D5B16AE-4F94-413B-ABE5-16C9B656DF02Q48101196-45152094-57D5-42C3-B52E-3470B6FED66BQ50856561-5F629E06-4143-43A7-9E2B-04B97DAD7E0AQ51765699-E53BCDBD-D523-43BE-BAE0-9E6DC12380BCQ57259323-032ECA73-E63A-4F30-8626-D3F2E4D4ACE0Q57259363-9E12310F-D33E-4689-9BC6-49D119E76ADDQ57259431-93BC7275-4838-4D7A-A5DE-EF41F1230199Q57259480-B2B411D1-AC70-41B5-AA8C-66B080B2316FQ57259497-4D1CE4C0-4077-490A-88B5-96BCE0991AB5Q57587982-BA933880-70AF-4E98-B620-D874A55F350DQ58125049-1FDBDEFA-2D46-4307-A668-EE5920C48BE7
P2860
Geographical distribution of TTR met30 carriers in northern Sweden: discrepancy between carrier frequency and prevalence rate.
description
1994 nî lūn-bûn
@nan
1994 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
Geographical distribution of T ...... frequency and prevalence rate.
@ast
Geographical distribution of T ...... frequency and prevalence rate.
@en
type
label
Geographical distribution of T ...... frequency and prevalence rate.
@ast
Geographical distribution of T ...... frequency and prevalence rate.
@en
prefLabel
Geographical distribution of T ...... frequency and prevalence rate.
@ast
Geographical distribution of T ...... frequency and prevalence rate.
@en
P2093
P2860
P356
P1476
Geographical distribution of T ...... frequency and prevalence rate.
@en
P2093
Andersson C
Holmgren G
Nylander PO
Saraiva MJ
Teixeira A
P2860
P304
P356
10.1136/JMG.31.5.351
P407
P577
1994-05-01T00:00:00Z